Tilray Brands, Inc.
$7.15
▲
6.68%
2026-04-21 09:50:00
www.tilray.com
NMS: TLRY
Explore Tilray Brands, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$833.32 M
Current Price
$7.15
52W High / Low
$23.2 / $3.51
Stock P/E
—
Book Value
$14.89
Dividend Yield
—
ROCE
-6.01%
ROE
-63.16%
Face Value
—
EPS
$-14.63
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,842
Beta
2.11
Debt / Equity
63.61
Current Ratio
2.79
Quick Ratio
1.49
Forward P/E
24.23
Price / Sales
0.89
Enterprise Value
$2.86 B
EV / EBITDA
160.91
EV / Revenue
3.33
Rating
Buy
Target Price
$10.04
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Akanda Corp. | $3.42 | — | $1.89 M | — | -102.48% | -60.86% | $209.03 / $2.29 | $22.67 |
| 2. | Gelteq Limited | $0.7 | — | $7.5 M | — | -31.25% | -42.99% | $4.11 / $0.64 | $1.09 |
| 3. | Eton Pharmaceuticals, Inc. | $25.28 | — | $683.2 M | — | -1.57% | -18.19% | $27.29 / $13.09 | $0.97 |
| 4. | Talphera, Inc. | $0.78 | — | $40.17 M | — | -52.04% | -1.15% | $1.57 / $0.38 | $0.34 |
| 5. | Amylyx Pharmaceuticals, Inc. | $17.57 | — | $2.03 B | — | -49.46% | -61.59% | $18.61 / $3.79 | $2.78 |
| 6. | Universe Pharmaceuticals INC | $3.32 | — | $1.9 M | — | -5.19% | -7.23% | $11 / $2 | $99.64 |
| 7. | Kamada Ltd. | $8.32 | 23.76 | $479.95 M | 3% | 7.92% | 7.64% | $9.35 / $6.35 | $4.66 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Sales | 206.73 M | 217.51 M | 209.5 M | 224.53 M | 185.78 M | — | — |
| Operating Profit | -19.87 M | -20.01 M | -10.87 M | -12.66 M | -31.4 M | — | — |
| Net Profit | -26.57 M | -44.93 M | -0.32 M | -1.27 B | -789.44 M | — | — |
| EPS in Rs | -0.23 | -0.39 | -0 | -10.92 | -6.77 | -1 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 821.31 M | 788.94 M | 627.12 M | 628.37 M |
| Operating Profit | -107.81 M | -112.76 M | -178.19 M | -233.27 M |
| Net Profit | -2.19 B | -244.98 M | -1.45 B | -476.8 M |
| EPS in Rs | -18.76 | -2.1 | -12.46 | -4.09 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.07 B | 4.22 B | 4.31 B | 5.45 B |
| Total Liabilities | 584.75 M | 778.49 M | 977.32 M | 1.01 B |
| Equity | 1.51 B | 3.44 B | 3.32 B | 4.4 B |
| Current Assets | 688.63 M | 677.71 M | 773.03 M | 803.5 M |
| Current Liabilities | 280.3 M | 299.17 M | 432.98 M | 280.34 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -94.6 M | -30.91 M | 7.91 M | -177.26 M |
| Investing CF | -46.72 M | 128.35 M | -285.11 M | -21.53 M |
| Financing CF | 133.51 M | -75.19 M | 70.16 M | 128.2 M |
| Free CF | -127.52 M | -60.15 M | -12.89 M | -211.33 M |
| Capex | -32.92 M | -29.25 M | -20.8 M | -34.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 25.8% | -0.2% | — | — |
| Earnings Growth % | 83.14% | -204.67% | — | — |
| Profit Margin % | -31.05% | -231.64% | -75.88% | — |
| Operating Margin % | -14.29% | -28.41% | -37.12% | — |
| Gross Margin % | 28.31% | 23.43% | 18.59% | — |
| EBITDA Margin % | -9.23% | -203.06% | -39.21% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-02 | 1:0.1 |